An extrapolation of MEDIPHARM LABS' 50-day and 200-day moving average lines suggests a GOLDEN CROSS should take place early next year.
According to The Globe and Mail, the target price for LABS is $0.10:
https://www.theglobeandmail.com/investing/markets/stocks/LABS-T/research/
This represents a 20% upside potential.
GLTA!
According to The Globe and Mail, the target price for LABS is $0.10:
https://www.theglobeandmail.com/investing/markets/stocks/LABS-T/research/
This represents a 20% upside potential.
GLTA!